Dr. Michael Lim on Toxicities of Checkpoint Inhibitors

Michael Lim, MD
Published: Monday, Nov 23, 2015



Michael Lim, MD, director of Brain Tumor Immunotherapy, associate professor of Neurosurgery, Johns Hopkins Medicine, discusses toxicities associated with checkpoint inhibitors for the treatment of glioblastoma.

Checkpoint inhibitors have the potential to improve quality of life and tumor control for patients with glioblastoma, says Lim. 

However, because checkpoint inhibitors release the breaks on the immune system they can induce autoimmune disorders. The two most concerning disorders that can result from the use of checkpoint inhibitors are colitis and nemunaitis, which can both be life threatening, says Lim.

To avoid serious complications from checkpoint inhibitors, oncologists need to monitor patients closely and act early, says Lim.



Michael Lim, MD, director of Brain Tumor Immunotherapy, associate professor of Neurosurgery, Johns Hopkins Medicine, discusses toxicities associated with checkpoint inhibitors for the treatment of glioblastoma.

Checkpoint inhibitors have the potential to improve quality of life and tumor control for patients with glioblastoma, says Lim. 

However, because checkpoint inhibitors release the breaks on the immune system they can induce autoimmune disorders. The two most concerning disorders that can result from the use of checkpoint inhibitors are colitis and nemunaitis, which can both be life threatening, says Lim.

To avoid serious complications from checkpoint inhibitors, oncologists need to monitor patients closely and act early, says Lim.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x